

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM414500

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
KASTLE THERAPEUTICS, LLC		01/19/2017	Limited Liability Company: DELAWARE
KASTLE THERAPEUTICS HOLDINGS, LLC		01/19/2017	Limited Liability Company: DELAWARE
KASTLE THERAPEUTICS INTERMEDIATE, LLC		01/19/2017	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	COMERICA BANK		
<b>Street Address:</b>	39200 W. SIX MILE ROAD		
<b>Internal Address:</b>	MC 7512		
<b>City:</b>	LIVONIA		
<b>State/Country:</b>	MICHIGAN		
<b>Postal Code:</b>	48152		
<b>Entity Type:</b>	TEXAS BANKING ASSOCIATION: TEXAS		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	4392642	KYNAMRO	
<b>Registration Number:</b>	4502626	KYNAMRO CORNERSTONE	
<b>Registration Number:</b>	4552496	KYNAMRO CORNERSTONE	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8585506420		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	858-550-6433		
<b>Email:</b>	jmfitzpatrick@cooley.com		
<b>Correspondent Name:</b>	JENNIFER FITZPATRICK		
<b>Address Line 1:</b>	C/O COOLEY LLP		
<b>Address Line 2:</b>	4401 EASTGATE MALL		
<b>Address Line 4:</b>	SAN DIEGO, CALIFORNIA 92121		
<b>ATTORNEY DOCKET NUMBER:</b>	036703-1826 KASTLE		
<b>NAME OF SUBMITTER:</b>	JENNIFER FITZPATRICK		

CH \$90.00 4392642

<b>SIGNATURE:</b>	/JENNIFER FITZPATRICK/
<b>DATE SIGNED:</b>	02/01/2017
<b>Total Attachments: 8</b> source=2017 01_IPSA_executed#page1.tif source=2017 01_IPSA_executed#page2.tif source=2017 01_IPSA_executed#page3.tif source=2017 01_IPSA_executed#page4.tif source=2017 01_IPSA_executed#page5.tif source=2017 01_IPSA_executed#page6.tif source=2017 01_IPSA_executed#page7.tif source=2017 01_IPSA_executed#page8.tif	

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of January 11 2017 by and between COMERICA BANK ("Bank") and KASTLE THERAPEUTICS, LLC, a Delaware limited liability company ("Therapeutics"), KASTLE THERAPEUTICS HOLDINGS, LLC, a Delaware limited liability company ("Holdings") and KASTLE THERAPUTICS INTERMEDIATE, LLC, a Delaware limited liability company ("Intermediate") (Therapeutics, Holdings and Intermediate each a "Grantor" and collectively, the "Grantors").

### RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantors (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and between Bank and Grantors dated of even date herewith (as the same may be amended, restated, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantors, but only upon the condition, among others, that each Grantor shall grant to Bank a security interest in certain Copyrights, Trademarks and Patents to secure the obligations of such Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, each Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of the Obligations, each Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure the Obligations, each Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Bank under the Loan Agreement. The rights and remedies of Bank with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Bank as a matter of law or equity. Each right, power and remedy of Bank provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Bank of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Bank, of any or all other rights, powers or remedies.

Each Grantor represents and warrants that Exhibits A, B, and C attached hereto set forth any and all intellectual property rights that, as of the date hereof, each Grantor has registered or filed an application with either the United States Patent and Trademark Office or the United States Copyright Office, as applicable.

This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute the same instrument.


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTORS:**

Address of Grantor:

**KASTLE THERAPEUTICS, LLC**


181 W. Madison, Suite 3400  
Chicago, IL 60602  
Attn: Scott Crawford

By:   
Name: BRYAN STUART  
Title: PRESIDENT

Address of Grantor:

**KASTLE THERAPEUTICS HOLDINGS, LLC**


c/o Kastle Therapeutics, LLC  
181 W. Madison, Suite 3400  
Chicago, IL 60602  
Attn: Scott Crawford

By:   
Name: BRYAN STUART  
Title: PRESIDENT

Address of Grantor:

**KASTLE THERAPEUTICS INTERMEDIATE, LLC**

c/o Kastle Therapeutics, LLC  
181 W. Madison, Suite 3400  
Chicago, IL 60602  
Attn: Scott Crawford


By:   
Name: BRYAN STUART  
Title: PRESIDENT

**BANK:**

Address of Bank:

**COMERICA BANK**

M/C 7512  
39200 W. Six Mile Road  
Livonia, MI 48152  
Attn: Livonia Operations Center

By:   
Name: Walter Weston  
Title: Vice President

[Signature page to Intellectual Property Security Agreement]

**EXHIBIT A**

**Copyrights**

<u>Description</u>	<u>Registration Number</u>	<u>Registration Date</u>
None.		

EXHIBIT B

Patents

<u>Owner</u>	<u>Country</u>	<u>Status</u>	<u>Application / Patent Number</u>	<u>Title</u>	<u>Grant Date</u>
Therapeutics	US	Abandoned	11/123,656	EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS	
Therapeutics	US	Abandoned	12/720,581	EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS	
Therapeutics	US	Published	14/500,729	EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS	
Therapeutics	US	Published	13/214,135	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Abandoned	11/200,710	METHODS FOR MODULATING LIPOPROTEIN AND CHOLESTEROL LEVELS IN HUMANS	
Therapeutics	US	Abandoned	11/573,537	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	WO	Closed	PCT/US2005/028342	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	

<u>Owner</u>	<u>Country</u>	<u>Status</u>	<u>Application / Patent Number</u>	<u>Title</u>	<u>Grant Date</u>
Therapeutics	US	Allowed	12/532,602	ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY	
Therapeutics	WO	Closed	PCT/US2008/058072	ADMINISTERING ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY	
Therapeutics	US	Closed	7,803,930	ANTISENSE MODULATON OF APOLIPOPROTEIN B EXPRESSION	9/28/10
Therapeutics	US	Pending	14/175,889	ANTISENSE MODULATON OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Abandoned	10/916,218	ANTISENSE MODULATON OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Issued	RE44,760	ANTISENSE MODULATON OF APOLIPOPROTEIN B EXPRESSION	2/11/14
Therapeutics	US	Issued	7,511,131	ANTISENSE MODULATON OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	WO	Closed	PCT/US03/036411	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Issued	7,888,324	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	2/15/11
Therapeutics	US	Abandoned	10/135,985	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	

<u>Owner</u>	<u>Country</u>	<u>Status</u>	<u>Application / Patent Number</u>	<u>Title</u>	<u>Grant Date</u>
Therapeutics	US	Issued	7,407,943	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	8/5/08
Therapeutics	US	Issued	8,735,364	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	5/27/14
Therapeutics	US	Published	14/286,621	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Abandoned	13/947,776	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	WO	Closed	PCT/US03/15493	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	WO	Closed	PCT/US02/24247	ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION	
Therapeutics	US	Closed	62/043,989	METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE	
Therapeutics	US	Closed	62/087,712	METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE	



<u>Owner</u>	<u>Country</u>	<u>Status</u>	<u>Application / Patent Number</u>	<u>Title</u>	<u>Grant Date</u>
Therapeutics *	US	Issued	8,916,694	SNPS OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION	12/23/14
Therapeutics *	US	Pending	14/558,402	SNPS OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION	
Therapeutics *	US	Abandoned	11/124,020	SNPS OF APOLIPOPROTEIN B AND MODULATION OF THEIR EXPRESSION	

\*Jointly owned by Therapeutics and Sequenom

**EXHIBIT C**

**Trademarks**

<b>Owner</b>	<b>Description</b>	<b>Registration/ Serial Number</b>	<b>Registration/ Application Date</b>
Therapeutics	KYNAMRO	4,392,642	08/27/2013
Therapeutics	KYNAMRO CORNERSTONE	4,502,626	03/25/14
Therapeutics	KYNAMRO CORNERSTONE	4,552,496	06/17/14